Literature DB >> 8363382

Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine.

H W Murray1, J Hariprashad, R E Fichtl.   

Abstract

In experimental visceral leishmaniasis, euthymic but not athymic (nude) BALB/c mice respond to conventional treatment with pentavalent antimony, indicating that the in vivo efficacy of antimony is T cell dependent. This finding correlates with frequent antimony treatment failures for T-cell-deficient patients with visceral leishmaniasis. To determine whether the in vivo efficacies of alternative antileishmanial agents also require T cells, Leishmania donovani-infected euthymic and nude BALB/c mice were treated with pentamidine or amphotericin B. Pentamidine induced leishmanistatic activity in euthymic mice but had little effect in nude mice. In contrast, amphotericin B exerted potent leishmanicidal activities in both euthymic and nude animals. These results suggest that amphotericin B may be of particular use for T-cell-deficient patients with visceral leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8363382      PMCID: PMC188002          DOI: 10.1128/AAC.37.7.1504

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of the literature.

Authors:  J Altés; A Salas; M Riera; M Udina; A Galmés; J Balanzat; A Ballesteros; J Buades; F Salvá; C Villalonga
Journal:  AIDS       Date:  1991-02       Impact factor: 4.177

2.  Visceral leishmaniasis in immunocompromised hosts.

Authors:  M L Fernández-Guerrero; J M Aguado; L Buzón; C Barros; C Montalbán; T Martín; E Bouza
Journal:  Am J Med       Date:  1987-12       Impact factor: 4.965

3.  Liposomal amphotericin B in drug-resistant visceral leishmaniasis.

Authors:  R N Davidson; S L Croft; A Scott; M Maini; A H Moody; A D Bryceson
Journal:  Lancet       Date:  1991-05-04       Impact factor: 79.321

4.  Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study.

Authors:  C P Thakur; M Kumar; P Kumar; B N Mishra; A K Pandey
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-04

5.  Amphotericin versus pentamidine in antimony-unresponsive kala-azar.

Authors:  M Mishra; U K Biswas; D N Jha; A B Khan
Journal:  Lancet       Date:  1992-11-21       Impact factor: 79.321

6.  The experimental chemotherapy of leishmaniasis, IV. The development of a rodent model for visceral infection.

Authors:  E R Trotter; W Peters; B L Robinson
Journal:  Ann Trop Med Parasitol       Date:  1980-04

7.  Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study.

Authors:  C P Thakur; M Kumar; A K Pandey
Journal:  Am J Trop Med Hyg       Date:  1991-10       Impact factor: 2.345

8.  An in vitro model for investigation of chemotherapeutic agents in leishmaniasis.

Authors:  J D Berman; D J Wyler
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

Review 9.  Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies.

Authors:  J D Berman
Journal:  Rev Infect Dis       Date:  1988 May-Jun

10.  Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony.

Authors:  H W Murray; J D Berman; S D Wright
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

View more
  14 in total

1.  Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation.

Authors:  H W Murray
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

Review 2.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

3.  Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.

Authors:  P Escobar; V Yardley; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 4.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

5.  Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis.

Authors:  H W Murray; J Hariprashad
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 6.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

7.  Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis.

Authors:  H W Murray; S Delph-Etienne
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

8.  Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis.

Authors:  Henry W Murray; Elaine B Brooks; Jennifer L DeVecchio; Frederick P Heinzel
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 9.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

10.  Multiple host defense defects in failure of C57BL/6 ep/ep (pale ear) mice to resolve visceral Leishmania donovani infection.

Authors:  H W Murray; J Hariprashad; D F McDermott; M Y Stoeckle
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.